Article Text

Download PDFPDF
Matrix metalloproteinases in destructive pulmonary pathology
  1. P T G Elkington,
  2. J S Friedland
  1. Department of Infectious Diseases, Imperial College Hammersmith, London, UK
  1. Correspondence to:
    Dr P T G Elkington
    Department of Infectious Diseases, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; p.elkington{at}imperial.ac.uk

Abstract

Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that have a number of important physiological roles including remodelling of the extracellular matrix, facilitating cell migration, cleaving cytokines, and activating defensins. However, excess MMP activity may lead to tissue destruction. The biology of MMP and the role of these proteases in normal pulmonary immunity are reviewed, and evidence that implicates excess MMP activity in causing matrix breakdown in chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), sarcoidosis, and tuberculosis is discussed. Evidence from both clinical studies and animal models showing that stromal and inflammatory cell MMP expression leads to immunopathology is examined, and the mechanisms by which excess MMP activity may be targeted to improve clinical outcomes are discussed.

  • MMP, matrix metalloproteinase
  • ECM, extracellular matrix
  • COPD, chronic obstructive pulmonary disease
  • ARDS, acute respiratory distress syndrome
  • TB, tuberculosis
  • MTb, Mycobacterium tuberculosis
  • BAL, bronchoalveolar lavage
  • matrix metalloproteinases
  • chronic obstructive pulmonary disease
  • tuberculosis
  • acute respiratory distress syndrome
  • sarcoidosis

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • PE was a Wellcome Trust Clinical Research Training Fellow. JSF is supported by the Wellcome Trust and the Medical Reseach Council (UK) for MMP research.

  • The authors have no competing financial interests.